These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1665123)

  • 61. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
    Thorburn CE; Edwards DI
    J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.
    Akaniro JC; Stutman HR; Arguedas AG; Vargas OM
    Antimicrob Agents Chemother; 1992 Feb; 36(2):255-61. PubMed ID: 1318674
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
    Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
    Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone.
    Visser MR; Rozenberg-Arska M; Beumer H; Hoepelman IM; Verhoef J
    Antimicrob Agents Chemother; 1991 May; 35(5):858-68. PubMed ID: 1854167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria.
    Eliopoulos GM; Wennersten CB; Moellering RC
    Diagn Microbiol Infect Dis; 1996 May; 25(1):35-41. PubMed ID: 8831043
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
    Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
    J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
    Rolston KV; Nguyen H; Messer M
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2137-41. PubMed ID: 2149921
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms.
    Benson CA; Beaudette F; Trenholm G
    J Antimicrob Chemother; 1987 Aug; 20(2):191-6. PubMed ID: 2822645
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
    Doebbeling BN; Pfaller MA; Bale MJ; Wenzel RP
    Eur J Clin Microbiol Infect Dis; 1990 Apr; 9(4):298-301. PubMed ID: 2112467
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.
    Child J; Andrews J; Boswell F; Brenwald N; Wise R
    J Antimicrob Chemother; 1995 Jun; 35(6):869-76. PubMed ID: 7559198
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.
    Foster JK; Lentino JR; Strodtman R; DiVincenzo C
    Antimicrob Agents Chemother; 1986 Dec; 30(6):823-7. PubMed ID: 3643771
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci.
    Ito T; Matsumoto M; Nishino T
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1522-5. PubMed ID: 7492097
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.
    Mattina R; Cocuzza CE; Cesana M; Bonfiglio G
    Chemotherapy; 1991; 37(4):260-9. PubMed ID: 1665122
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vitro activity of fluoroquinolones against gram-positive bacteria.
    Eliopoulos GM
    Drugs; 1995; 49 Suppl 2():48-57. PubMed ID: 8549407
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Newer agents against methicillin and/or gentamicin-resistant and -susceptible staphylococci.
    Chandrasekar PH; Sluchak JA
    Chemotherapy; 1989; 35(5):333-7. PubMed ID: 2551600
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
    Entenza JM; Marchetti O; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1889-94. PubMed ID: 9687379
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In vitro activity of A-56619 and A-56620 against multi-resistant and routine clinical isolates.
    Fernandes CJ; Wilson RD; Ackerman VP
    Chemotherapy; 1988; 34(3):216-28. PubMed ID: 3416660
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
    Weller TM; Andrews JM; Jevons G; Wise R
    J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.